Elisabeth Perzborn
Overview
Explore the profile of Elisabeth Perzborn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1067
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morihara R, Yamashita T, Kono S, Shang J, Nakano Y, Sato K, et al.
J Neurosci Res
. 2016 Dec;
95(9):1818-1828.
PMID: 28035779
This study aimed to assess the risk of intracerebral hemorrhage (ICH) after tissue-type plasminogen activator (tPA) treatment in rivaroxaban compared with warfarin-pretreated male Wistar rat brain after ischemia in relation...
2.
Ellinghaus P, Perzborn E, Hauenschild P, Gerdes C, Heitmeier S, Visser M, et al.
Thromb Res
. 2016 May;
142:44-51.
PMID: 27131284
Introduction: In addition to its central role in coagulation, thrombin is involved in non-hemostatic activities such as inflammation. Direct inhibition of thrombin activity (e.g. with dabigatran) or reducing its generation...
3.
Perzborn E, Heitmeier S, Laux V
J Cardiovasc Pharmacol Ther
. 2015 Apr;
20(6):554-62.
PMID: 25848131
Introduction: Activation of coagulation and platelets is closely linked, and arterial thrombosis involves coagulation activation as well as platelet activation and aggregation. In these studies, we investigated the possible synergistic...
4.
Perzborn E, Heitmeier S, Laux V, Buchmuller A
Thromb Res
. 2014 Feb;
133(4):671-81.
PMID: 24529498
Introduction: Anticoagulation therapies carry a risk of bleeding; reversal agents may be beneficial in cases of severe bleeding even for anticoagulants with a relatively short half-life, such as the oral...
5.
Kubitza D, Perzborn E, Berkowitz S
Front Pharmacol
. 2013 Dec;
4:145.
PMID: 24324436
Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations...
6.
Korber M, Langer E, Ziemer S, Perzborn E, Gericke C, von Heymann C
Clin Appl Thromb Hemost
. 2013 Jul;
20(7):735-40.
PMID: 23832064
Background: Rivaroxaban (Xarelto, Bayer HealthCare, Leverkusen, Germany) is a new oral anticoagulant drug. Anticoagulants may cause bleeding, thereby requiring reliable monitoring and efficient therapy. We investigated thromboelastometry versus routine coagulation...
7.
Samama M, Contant G, Spiro T, Perzborn E, Le Flem L, Guinet C, et al.
Thromb J
. 2013 Jul;
11(1):11.
PMID: 23822763
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases...
8.
Sarich T, Peters G, Berkowitz S, Misselwitz F, Nessel C, Burton P, et al.
Ann N Y Acad Sci
. 2013 May;
1291:42-55.
PMID: 23701516
The development of rivaroxaban (XARELTO®) is an important new medical advance in the field of oral anticoagulation. Thrombosis-mediated conditions constitute a major burden for patients, healthcare systems, and society. For...
9.
Perzborn E, Gruber A, Tinel H, Marzec U, Buetehorn U, Buchmueller A, et al.
Thromb Haemost
. 2013 May;
110(1):162-72.
PMID: 23636219
Rivaroxaban is an oral, direct factor Xa inhibitor for the management of thromboembolic disorders. Despite its short half-life, the ability to reverse rivaroxaban anticoagulation could be beneficial in life-threatening emergencies....
10.
Zhou W, Zorn M, Nawroth P, Butehorn U, Perzborn E, Heitmeier S, et al.
Stroke
. 2013 Jan;
44(3):771-8.
PMID: 23339956
Background And Purpose: Rivaroxaban has recently been approved for stroke prevention in atrial fibrillation. However, lack of an effective antidote represents a major concern in the event of intracerebral hemorrhage...